Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Type 2 diabetes mellitus~* Glycosylated hemoglobin above the upper limit of normal (ie, the local equivalent of 6.5% for)~* Established history of macrovascular disease, defined as 1 or more of:~  * Myocardial infarction at least 6 months before entry into the study.~ * Stroke at least 6 months before entry into the study~ * Percutaneous coronary intervention or coronary artery bypass graft at least 6 months before entry into the study.~ * Acute coronary syndrome at least 3 months before entry into the study.~ * Objective evidence of coronary artery disease.~ * Peripheral arterial obstructive disease~Exclusion Criteria~* Signs of type 1 diabetes.~* Patients prescribed insulin as sole therapy for glycemic control of diabetes for 2 weeks or more at any time in the previous 3 months.~* Myocardial infarction, stroke, coronary artery bypass graft, or percutaneous cardiac intervention in the 6 months prior to enrolment.~* Acute coronary syndrome in the 3 months prior to enrolment.~* Heart failure at entry defined as patient having a New York Heart Association functional score of II or above.~* Had an appointment for a coronary angiogram or endovascular or surgical intervention.~* Leg ulcers, gangrene, or ischemic rest pain.~* Had an appointment for an angiogram or endovascular or surgical intervention for leg ischemia.~* Had undergone a major operation (defined as a surgical procedure lasting for more than 30 minutes) at any time in the previous 4 weeks.~* Significantly impaired hepatic function, defined as alanine aminotransferase greater than 2.5 times the upper limit of normal.~* Familial polyposis coli.~* Required dialysis.~* History of alcohol or drug abuse.~* Any other intercurrent disease believed to be likely to have a significant impact on the patient's life expectancy during the course of the study (eg, cancer).~* Patient was undergoing follow-up as part of another clinical trial or less than 3 months had elapsed since the last dose of an investigational drug or procedure.~* Hypersensitivity to pioglitazone or other TZD.~* Current use of pioglitazone or other TZD.~* Patient was known to be infected with human immunodeficiency virus or was known to have viral hepatitis.~* Women who were any of the following: pregnant, breast feeding, wished to become pregnant during the course of the study or of childbearing potential and not planning to use a reliable method of contraception throughout the study.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Pioglitazone QD (Type: EXPERIMENTAL): None
- Placebo QD (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).